The US Food and Drug Administration has approved Xarelto (rivaroxaban) to reduce stroke risk in those with non-valvular atrial fibrillation (afib unrelated to heart valve problems). Xarelto is now the second oral alternative to warfarin (Coumadin) and offers an option for those unable to take warfarin or dabigatran. Xarelto is the first once-a-day alternative to …
Read More
In this important video interview at Venice Arrhythmias, Professor Gregory Lip discusses the importance of the CHA2DS2-VASc scoring tool for predicting atrial fibrillation stroke risk and why aspirin is not appropriate for preventing strokes. Watch the video at: Professor Gregory Lip Discusses CHA2DS2-VASc Tool for Predicting Stroke Risk in Atrial Fibrillation — Video
Read More
Raising afib awareness is intensely personal for StopAfib.org founder, Mellanie True Hills, and led her to create the first Atrial Fibrillation Awareness Month in 2007. Working with other organizations, Hills helped urge the U.S. Senate to officially designate National Atrial Fibrillation Awareness Month in September 2009. This roundup recaps what happened during Afib Month 2011, …
Read More
September is Atrial Fibrillation Awareness Month. Lots of folks don’t know too much about the condition, which is an irregular heart beat that can lead to serious complications such as dementia, heart failure, stroke or even death. To help spread the word, StopAfib.org presents these 10 afib facts and figures that will probably surprise even …
Read More
By Mellanie True Hills September is Atrial Fibrillation Awareness Month. A lot of folks may ask: Why do we need a month devoted to afib? Or, even, what is atrial fibrillation, anyway? Afib is an irregular heart beat that can lead to serious complications, such as dementia, heart failure, stroke, or even death. Too many …
Read More
The US Food & Drug Administration (FDA) Advisory Committee just voted 9-2, with 1 abstaining, to recommend that the FDA approve rivaroxaban (Xarelto) for prevention of atrial fibrillation strokes. See our full story, now up at: FDA Panel Votes for Rivaroxaban: Atrial Fibrillation Patients May Soon Have Two Alternatives to Warfarin for Stroke Prevention
Read More
StopAfib.org is among a group of experts calling today for urgent action to prevent an atrial fibrillation stroke crisis in Latin America. Action for Stroke Prevention, a group of health experts from across the globe, is launching a new report, How Can We Avoid a Stroke Crisis in Latin America?, at the International Society for …
Read More
Just ahead of the FDA Advisory Committee hearing on rivaroxaban for stroke prevention in atrial fibrillation, we report in more depth on the ROCKET-AF trial results published recently in the New England Journal of Medicine. Rivaroxaban was shown to be as effective as warfarin (Coumadin) for stroke prevention in a high-risk afib population. To learn …
Read More
In honor of Atrial Fibrillation (Afib) Awareness Month, Team AFib would like to invite you to our second webinar, “AFib CARE: Creating A Role for Effective Teams”, taking place at 1:00 p.m. ET on Wednesday, September 14 and hosted by StopAfib.org. To learn more, see: Join Team AFib’s Atrial Fibrillation Webinar, “AFib CARE: Creating A …
Read More
In her first regular Patient Perspective column, which appears in the August issue of EP Lab Digest, StopAfib.org founder Mellanie True Hills explores a concern in the atrial fibrillation patient community that staying in afib long term could be a "death sentence." In addition, she talks about the upcoming National Atrial Fibrillation Awareness Month, which …
Read More